Induced pluripotent stem cell derived cardiomyocytes: a new therapy for “no-option” end stage heart failure

  • Chong, James J.H. (Primary Chief Investigator (PCI))
  • Chow, Clara (Chief Investigator (CI))
  • Gray, Peter (Chief Investigator (CI))
  • Trounson, Alan (Chief Investigator (CI))
  • Palpant, Nathan J. (Chief Investigator (CI))
  • Graham, Robert (Chief Investigator (CI))
  • McDonald, Peter (Chief Investigator (CI))
  • Shiba, Yugi (Chief Investigator (CI))

Project: Research

Project Details

Project Description

Cardiovascular disease (CVD) accounts for more deaths and more health expenditure than any other disease or injury group in Australia and is an Australian National Health Priority Area. Heart failure costs in Australia are over $1 Billion p.a. with 50% mortality within 1 year (stage IV disease). This arises from the heart’s limited capacity for self-repair. Whilst heart transplantation is an option, there will never be enough donor hearts to treat the huge and increasing demand of our ageing population. A potential solution is to use stem cells to regenerate damaged
myocardium. This could dramatically decrease premature death and health care costs from hospital readmissions.
StatusActive
Effective start/end date1/03/22 → 29/03/27

Keywords

  • Cardiovascular disease
  • pluripotent stem cells
  • cardiomyocytes